UCB sells off production plant and a clutch of older meds in China for $680M

Restructuring seems to be the name of the game for many large drugmakers these days, and Belgium-based UCB is no exception.

Early Monday, UCB revealed that it’s selling off its mature neurology and allergy business in mainland China to local healthcare asset manager CBC Group and Abu Dhabi-based investment firm Mubadala.

UCB is in line to receive $680 million from the transaction, which covers the seizure drugs Keppra and Vimpat, Neupro for Parkinson’s disease and restless leg syndrome, and the allergy meds Zyrtec and Xyzal.

UCB is also pawning off a manufacturing site in the city of Zhuhai in China’s Guangdong Province as part of the divestment deal, the company said...

Today's Sponsors

Today's Sponsor